Payment overview · 2025
General Payments
$2,411.46
94 reported records · 20 companies
Healthcare provider profile · identity verified
Fouad N Aoude, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOPEDALE, MA · NPI 1871764399
Verified facts
What the public records show
CMS Open Payments records show Fouad N Aoude, M.D. received $2,411.46 in general payments during 2025 across 94 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $736.84 | 30.6% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $292.22 | 12.1% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $212.31 | 8.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $199.63 | 8.3% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $179.81 | 7.5% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $128.85 | 5.3% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $109.42 | 4.5% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $99.48 | 4.1% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $87.62 | 3.6% | 5 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $83.32 | 3.5% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.76 | 3.1% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $67.73 | 2.8% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.04 | 0.9% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.21 | 0.8% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $20.02 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.00 | 0.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.05 | 0.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.30 | 0.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.44 | 0.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.41 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,411.46 | 94 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $324.32 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $288.04 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $268.52 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $265.52 | 9 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $212.31 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $153.12 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.65 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $120.11 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $109.42 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $107.53 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $99.48 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $87.62 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $85.56 | 4 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $83.32 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $77.39 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $73.76 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $67.73 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.64 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $26.69 | 3 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $4.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 367 | 106 |
| Lisinopril | Lisinopril | 294 | 75 |
| Omeprazole | Omeprazole | 274 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 60 |
| Losartan Potassium | Losartan Potassium | 219 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 53 |
| Alprazolam | Alprazolam | 190 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 51 |
| Simvastatin | Simvastatin | 182 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 33 |
| Lorazepam | Lorazepam | 116 | 21 |
| Furosemide | Furosemide | 112 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 106 | 28 |
| Gabapentin | Gabapentin | 103 | 22 |
| Trazodone Hcl | Trazodone Hcl | 102 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 33 |
| Metformin Hcl | Metformin Hcl | 88 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 25 |
| Atenolol | Atenolol | 82 | 23 |
| Allopurinol | Allopurinol | 79 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 20 |
| Metformin Hcl Er | Metformin Hcl | 77 | 21 |
| Azithromycin | Azithromycin | 75 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 13 |
| Tramadol Hcl | Tramadol Hcl | 69 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 27 |
| Ibuprofen | Ibuprofen | 64 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 15 |
| Glipizide | Glipizide | 51 | 14 |
| Prednisone | Prednisone | 51 | 36 |
| Sertraline Hcl | Sertraline Hcl | 51 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 11 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Lovastatin | Lovastatin | 45 | 11 |
| Potassium Chloride | Potassium Chloride | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Eliquis | Apixaban | 42 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 31 |
| Glipizide Er | Glipizide | 41 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Famotidine | Famotidine | 31 | 11 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Naproxen | Naproxen | 18 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Betaxolol Hcl | Betaxolol Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,411.46 · 94 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, General - Pain Management, IBSRELA, JARDIANCE, JATENZO, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, PAXLOVID, PURIFIED CORTROPHIN GEL, QULIPTA, REZDIFFRA, The Cologuard Plus Collection Kit, Tlando, UBRELVY, VOQUEZNA, VYEPTI, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error